Journals / Diagnostic and Interventional Radiology / 2017 / Cilt: 23 - Sayı: 1

Multiparametric MRI in differentiating pulmonary artery sarcoma and pulmonary thromboembolism: a preliminary experience

Pages
15–21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION Hyperintense filling defect in main pulmonary artery on fat-suppressed T2-weighted imaging and DWI and contrast enhancement may help to discriminate PAS from PTE.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PURPOSE We aimed to define multiparametric magnetic resonance imaging (MRI) findings to differentiate between pulmonary artery sarcoma (PAS) and pulmonary thromboembolism (PTE).
📊
Key Findings & Data:MRI protocol included an unenhanced sequence, diffusion-weighted imaging (DWI, b=800 s/mm2 ) and a dynamic contrast-enhanced sequence.
💡
Conclusion & Impact:CONCLUSION Hyperintense filling defect in main pulmonary artery on fat-suppressed T2-weighted imaging and DWI and contrast enhancement may help to discriminate PAS from PTE.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

PURPOSE We aimed to define multiparametric magnetic resonance imaging (MRI) findings to differentiate between pulmonary artery sarcoma (PAS) and pulmonary thromboembolism (PTE). METHODS Eleven patients with suspected PTE were prospectively included to undergo pulmonary MRI before surgery or biopsy. MRI protocol included an unenhanced sequence, diffusion-weighted imaging (DWI, b=800 s/mm2 ) and a dynamic contrast-enhanced sequence. Morphologic characteristics including distribution, filling defect, and intensity were observed on T1-, T2-, and fat-suppressed T2-weighted imaging, DWI, and contrast-enhanced MRI. Apparent diffusion coefficient (ADC) values were calculated. RESULTS Six patients were pathologically diagnosed as PAS and the other five as chronic PTE. There were no significant differences in age, gender, presenting symptoms, D-dimer, and N-terminal probrain natriuretic peptide between the two groups (P > 0.05). Among MRI findings that were tested for their ability to diagnose PAS, area under the curve (AUC) was significantly higher than 0.5 for main pulmonary artery involvement (AUC, 0.83±0.13; P = 0.011), hyperintensity on fat-suppressed T2-weighted imaging (AUC, 0.82±0.14; P = 0.025), hyperintensity on DWI (AUC, 0.88±0.12; P = 0.002), contrast enhancement (AUC, 0.92±0.10; P < 0.001) and pleural effusion (AUC, 0.82±0.14; P = 0.025). Moreover, grape-like appearance in distal pulmonary artery and cardiac invasion had 100% specificity for diagnosis of PAS. However, ADC value of PAS was not significantly different than that of chronic PTE (U, 12.00; P = 0.584). CONCLUSION Hyperintense filling defect in main pulmonary artery on fat-suppressed T2-weighted imaging and DWI and contrast enhancement may help to discriminate PAS from PTE.

🔖

Cite This Article

LİU, M., LUO, C., WANG, Y., GUO, X., MA, Z., YANG, Y., ZHANG, T. (2017). Multiparametric MRI in differentiating pulmonary artery sarcoma and pulmonary thromboembolism: a preliminary experience. Diagnostic and Interventional Radiology, Cilt: 23 - Sayı: 1, 15–21. https://ajindex.com/articles/350038

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Bendel EC, Maleszewski JJ, Araoz PA. Imaging sarcomas of the great vessels and heart. Semin Ultrasound CT MR 2011; 32:377-404. [CrossRef] 2. Tueller C, Fischer Biner R, Minder S, et al. FDG-PET in diagnostic work-up of pulmonary artery sarcomas. Eur Respir J 2010; 35:444-446. [CrossRef] 3. Benz MR, Tchekmedyian N, Eilber FC, et al. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol 2009; 21:345-351. [CrossRef] 4. Blackmon SH, Rice DC, Correa AM, et al. Management of primary pulmonary artery sarcomas. Ann Thorac Surg 2009; 87:977-984. [CrossRef] 5. Krüger I, Borowski A, Horst M, et al. Symptoms, diagnosis, and therapy of primary sarcomas of the pulmonary artery. Thorac Cardiovasc Surg 1990; 38:91-95. [CrossRef] 6. Wang Y, Rossman PJ, Grimm RC, Riederer SJ, Ehman RL. Navigator-echo-based real time and triggering for reduction of respiration effects in three dimensional coronary MR angiography. Radiology 1996; 198:55-60. [CrossRef] 7. Yi CA, Lee KS, Choe YH, Han D, Kwon OJ, Kim S. Computed tomography in pulmonary artery sarcoma distinguishing features from pulmonary embolic disease. J Comput Assist Tomogr 2004; 28:34-39. [CrossRef] 8. Cox JE, Chiles C, Aquino SL, Savage P, Oaks T. Pulmonary artery sarcomas: A review of clinical and radiologic features. J Comput Assist Tomogr 1997; 21:750-755. [CrossRef] 9. Smith WS, Lesar MS, Travis WD, Lubbers P, et al. MR and CT findings in pulmonary artery sarcoma. J Comput Assist Tomogr 1989; 13:906-909. [CrossRef] 10. Wittram C, Maher MM, Yoo AJ, Kalra MK, Shepard JA, McLoud TC. CT angiography of pulmonary embolism: diagnostic criteria and causes of misdiagnosis. Radiographics 2004; 24:1219-1238. [CrossRef] 11. Chow B, Wittram C, Lee VW. Unilateral absence of pulmonary perfusion mimicking pulmonary embolism. AJR Am J Roentgenol 2001; 176:712. [CrossRef] 12. Gan HL, Zhang JQ, Huang XY, Yu W. The wall eclipsing sign on pulmonary artery computed tomography angiography is pathognomonic for pulmonary artery sarcoma. PLoS One 2013; 8:e83200. [CrossRef] 13. Sandrasegaran K, Tahir B, Nutakki K, et al. Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol 2013; 201:1211-1219. [CrossRef] 14. Bogaert J, Dymarkowski S. Cardiac Masses. In: Bogaert J, Dymarkowski S, Taylor AM, Muthurangu V, eds. Clinical cardiac MRI. 2nd ed. Berlin:Springer-Verlag, 2012; 411-